Mlp Saglik Hizmetleri As Class B · BIST:MPARK

Mlp Saglik Hizmetleri As Class B — MLP Care — 9M 2019 Earnings Presentation

26 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Nov 8, 2019

  1. Slide 1: MLP Care 9M 2019 Presentation

    MLP Care 9M 2019 Presentation 8 November 2019

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava

  3. Slide 3: Muharrem Usta, Chairman & CEO

    Muharrem Usta Chairman & CEO 3

  4. Slide 4: Executive Summary

    Executive Summary  Real growth of revenue and EBITDA exceeding inflation in the thoughest quarter of the year due to seasonality and regional conflicts • Revenue up 14% in Q3 2019, up 21% in 9M 2019 • Adj. EBITDA1 without foreign exchange effect of other income/expenses from operating activities up

  5. Slide 5: The Largest Private Healthcare Service Provider in Turkey

    The Largest Private Healthcare Service Provider in Turkey +2 +500 New Hospital New Beds in 2018 in 2018 17 Cities 20,000+ Staff 1 31 Hospitals +6,000 in Total Beds in Total 2,200+ Doctors ¹ Includes managed hospitals, full time and part-time staff 5

  6. Slide 6: Double Digit Growth in Majority of Payor Types

    Double Digit Growth in Majority of Payor Types Revenue Breakdown by Payor Type – 9M 2019 Other; 24%  Revenue from PMI, Top-up & 9% Contracted Institutions grew Medical SSI; by 40% in Q3 2019 Tourism; 26% 12%  Medical Tourism grew by 4% 18% in Q3 2019 47%  SSI Insurance allows for a wide addressab

  7. Slide 7: # of People with Top-up Insurance Exceeds 1.1 million

    # of People with Top-up Insurance Exceeds 1.1 million # of People with Insurance (PMI and Top-up) in Turkey – 000s Growth CAGR (2014-2018) (9M 2018-9M 2019) 3,144 3,368 4000,0 2,214 9.2% 2,974 13.2% 3500,0 3000,0 920 1,126 2500,0 64 94.5% 807 39.4% 2000,0 1500,0 0.9% 2,224 3.5% 1000,0 2,150 2,166 2,

  8. Slide 8: Medical Tourism Revenue Up 47% in 9M 2019

    Medical Tourism Revenue Up 47% in 9M 2019 Medical Tourism Revenue (TLm) 28.7% 350 18.3%  Diversified and Balanced 300 64 Geography. Patients comes from: 250 41 200 150 330 35% 32% Europe 47.0% 100 224 Middle East and Africa 50 34% Former CIS and the Rest 0 9M 2018 Volume & Mix Price & Fx 9M 2019 

  9. Slide 9: Burcu Öztürk, CFO

    Burcu Oztiirk CFO MLPCARE

  10. Slide 10: Revenue Up 21% in 9M 2019

    Revenue Up 21% in 9M 2019 Revenue (TLm) 22.3% 20.6% 3000 3,018 15.0% 2500 2,716 2,468 2000 14.3% 2,251 1500 1000 991 862 500 782 893 0 Q3 2018 Q3 2019 9M 2018 9M 2019 Revenue Including Managed Hospitals: Revenues of Florya, ISU Gaziosmanpaşa and ISU Bahçeşehir were included Denotes growth of Revenue

  11. Slide 11: EBITDA Up 29% in 9M 2019

    EBITDA Up 29% in 9M 2019 EBITDA (TLm) 1 25.4% 600 28.6% 17.5% 601 500 592 16.7% 511 400 29.4% 411 472 300 7.3% 353 403 313 200 122 100 102 110 0 95 Q3 2018 Q3 2019 9M 2018 9M 2019 9M 2018 9M 2019 (IFRS 16) (IFRS 16) 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact on relevant period a

  12. Slide 12: Strong Revenue Growth in 9M 2019

    Strong Revenue Growth in 9M 2019 Domestic Patient Medical Tourism Ancillary Business Revenues Revenues 18.9% 51.8% 23.6% 17.9% 17.1% 21.5% 47.0% (18.7%) 18.0% 239 17.7% 2,147 330 716 117 60 Q3 2019 9M 2019 Q3 2019 9M 2019 Q3 2019 9M 2019 Growth Continued in Q3 2019 Continued to Attract Foreign Stron

  13. Slide 13: Strong Improvement in Both ARPV and ARPP in 9M 2019

    Strong Improvement in Both ARPV and ARPP in 9M 2019  Outpatient and Inpatient revenues made up 41% and 59% of total Domestic Hospital Business Revenues in 9M 2019. Outpatient Revenues (TLm) Inpatient Revenues (TLm) 18.6% 16.1% 17.5% 12.8% 1.0% 3.3% 129 141 8 36 875 1,273 738 1,096 9M 2018 Volume &

  14. Slide 14: Smart Cost Management Results in Profitability Growth

    Smart Cost Management Results in Profitability Growth Cost of Service and G&A Expenses as a % of  Material costs as a % of revenue Revenues increased in 9M 2019 due to the Adj. EBITDA Margin 15.7% 15.2% inflation adjustment for drugs in February 2019, which accounts around 30% of the total material

  15. Slide 15: Continued to Deleverage Balance Sheet in 9M 2019

    Continued to Deleverage Balance Sheet in 9M 2019 NET DEBT FX BASED NET DEBT (in EUR m) 2018 1 9M 2019 1 250,0 EUR72m EUR82m 204 (TL437m) (TL504m) 200,0 150,0 34% 35% Percentage 66% 100,0 82 65% 72 50,0 TL806m TL1,000m Local Currency Local Currency - 2017 2018 9M 2019 Hard Currency Hard Currency Nomi

  16. Slide 16: FX Position of Income Statement – Excluding IFRS 16

    FX Position of Income Statement – Excluding IFRS 16 Hard Hard Currency as % TLm 9M 2019 (TLm) Currency of total revenues 2,147 - 30 Eylül Share of Medical Tourism Revenue in Domestic Hospital Revenue - Foreign Medical Tourism 330 330 12% 2018 Total Revenue Ancillary 239 - - increased to 12% in Total

  17. Slide 17: FX Position of Income Statement – Including IFRS 16

    FX Position of Income Statement – Including IFRS 16 Hard Hard Currency as % TLm 9M 2019 (TLm) Currency of total revenues 2,147 - 30 Eylül Share of Medical Tourism Revenue in Domestic Hospital Revenue - Foreign Medical Tourism 330 330 12% 2018 Total Revenue Ancillary 239 - - increased to 12% in Total

  18. Slide 18: Total Capex and Maintenance Capex Decreased

    Total Capex and Maintenance Capex Decreased Maintenance Capex (TLm) Total Capex (TLm) Operating Cash Flow / EBITDA 2.9% 10.2% 61.0% 250 49.1% 70 1.6% 250 60 200 215 65 200 230 4.5% 202 50 150 40 150 44 30 100 100 123 20 10 50 50 - - - 9M 2018 9M 2019 9M 2018 9M 2019 9M 2018 9M 2019 % of Revenue % of

  19. Slide 19: Outlook & Prospects

    Outlook & Prospects Muharrem Usta – Chairman & CEO 19

  20. Slide 20: Outlook & Prospects

    Outlook & Prospects We use our available resources and focus on efficient growth. Our targets are: Operational targets  Accelerate Foreign Medical Tourism (FMT)  Focus on the ramp-up of the new opened hospitals  Increase efficiency of the business through digitalization (invoicing/collection auto

  21. Slide 21: CARE

    CARE

  22. Slide 22: Closing Remarks

    Closing Remarks Muharrem Usta – Chairman & CEO 22

  23. Slide 23: Thank You!

    Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/

  24. Slide 24: Historical P&L Statements

    Historical P&L Statements TLm Unaudited Unaudited Unaudited 9M 20191 9M 2019 9M 2018 Q3 20191 Q3 2019 Q3 2018 Revenue 2,716 2,716 2,251 893 893 782 Cost of service (-) (2,098) (2,248) (1,902) (698) (748) (671) Gross profit 617 467 349 196 146 110 General administration expenses (-) (218) (218) (189)

  25. Slide 25: Historical Balance Sheet

    Historical Balance Sheet Unaudited Unaudited Audited TLm September 30, 20191 September 30, 2019 December 31, 2018 Cash and cash equivalents 231 231 223 Trade receivables 966 966 899 Inventory 83 83 80 Short term other assets 312 312 276 Current assets 1,592 1,592 1,479 Tangible and intangible fixed

  26. Slide 26: Reconciliation from Reported EBITDA to Adjusted EBITDA

    Reconciliation from Reported EBITDA to Adjusted EBITDA TLm 9M 20191 9M 2019 9M 2018 Q3 20191 Q3 2019 Q3 2018 Net profit / (loss) (20) (47) (143) 5 (8) (135) Tax income from operations (5) (12) (66) (3) (6) (20) Depreciation and amortization of tangible and intangible fixed assets 198 161 141 69 59 5

MLP Care — 9M 2019 Earnings Presentation on 6ix